JD Supra

FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs

On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from ...
Nasdaq

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce ...
JD Supra

FDA Signals it Has No Appetite to Add Popular GLP-1 Drug Substances to the 503B Bulks List

FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The proposal would materially limit 503B bulk compounding of these GLP-1 products. Comments on the ...
The Journal News

Rixa Health Announces National Expansion of Compound Tirzepatide Solutions to Address Increasing Demand for Metabolic Support

Rixa Health, a telehealth-focused healthcare provider specializing in metabolic health and medical weight management, has announced the national expansion of its physician-supervised pathway for ...
NBC Los Angeles

FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions

Baillies, a human resources specialist based in Milwaukee, Wisconsin, has been attempting to lose weight and dealing with chronic autoimmune issues for years, so she turned to a cheaper alternative: a ...